LEUCOMAX INJ
Brand:
LEUCOMAX INJ
Manufacturer:
NOVARTIS
Manufacturer Details
NOVARTIS
Compositions:
Molgramostin-(recombinant hum glanulocyte macrophage colony stimulating factor- GM-CSF),
150mcg(1.67 million units)/ 300mcg (3.33 million units)/450 mcg (4.44 million units) ,
|
Strength
|
Rate
|
Packing Style
|
|
150mcg
|
2650.00
|
vial injection
|
|
300mcg
|
5300.00
|
vial injection
|
|
450mcg
|
6500.00
|
vial injection
|
List of Related Indications:
- Chemotherapy induced neutropenia
List Of Drugs:
- Molgramostim-recomb Hum glanulocyte macrophage stim factor
Indication Type Description:
Drug Interaction:
As the drug causes decrease in serum albumin,adjust dosage of co-administered drugs which are highly bound to serum albumin. Reverse netropenia and reduces chances of opportunistic infections produced by cytotoxic chemotherapy.
Indication:
Acceleration of myeloid recovery following bone marrow transplant
Adverse Reaction:
Pericarditis,pulmonary thromboembolism. Onchogenic potential. Fever, nausea, rash, musculo-skeletal pain, dysuria. S/c injection: Local induration pain. I/v infusion: Phelebitis.
Contra-Indications:
Hypersens to the drug or any component of the formulation. Myeloid malignancies. Special precautions: To be administred strictly under medical supervision.
Dosages/ Overdosage Etc:
Accelration of myeloid recovery following bone marrow transplant
Dosage-
60000 -110000 units/kg daily starting 24 hrs after last dose of chemotherapy continued for 7-10 days
